antibodies -online.com





anti-EIF4G1 antibody (pSer1232)





Go to Product page

\sim			
()	/Or	1/1/	7//
\cup	ver	AIC	- v v

Alternative Name:

· · · · · · · · · · · · · · · · · · ·		
Quantity:	100 μL	
Target:	EIF4G1	
Binding Specificity:	pSer1232	
Reactivity:	Human	
Host:	Rabbit	
Clonality:	Polyclonal	
Conjugate:	This EIF4G1 antibody is un-conjugated	
Application:	Immunohistochemistry (IHC), Western Blotting (WB), ELISA	
Product Details		
lmmunogen:	Peptide sequence around phosphorylation site of serine 1232 (P-V-S(p)-P-L) derived from Human eIF4G.	
Isotype:	IgG	
Cross-Reactivity:	Human	
Purification:	Antibodies were produced by immunizing rabbits with synthetic phosphopeptide and KLH conjugates. Antibodies were purified by affinity-chromatography using epitope-specific phosphopeptide. Non-phospho specific antibodies were removed by chromatogramphy usi	
Target Details		
Target:	EIF4G1	

EIF4G1 (EIF4G1 Products)

Target Details

Background:

Background: eIF4F is a multi-subunit complex, the composition of which varies with external and internal environmental conditions. It is composed of at least EIF4A, EIF4E and EIF4G1/EIF4G3. Interacts with eIF3, mutually exclusive with EIF4A1 or EIFA2, EIF4E and through its N-terminus with PAPBC1. Interacts through its C-terminus with the serine/threonine kinases MKNK1, and with MKNK2. Appears to act as a scaffold protein, holding these enzymes in place to phosphorylate EIF4E. Non-phosphorylated EIF4EBP1 competes with EIF4G1/EIF4G3 to interact with EIF4E, insulin stimulated MAP-kinase (MAPK1 and MAPK3) phosphorylation of EIF4EBP1 causes dissociation of the complex allowing EIF4G1/EIF4G3 to bind and consequent initiation of translation. EIF4G1/EIF4G3 interacts with PABPC1 to bring about circularization of the mRNA. Rapamycin can attenuate insulin stimulation mediated by FKBPs. Interacts with EIF4E3. Interacts with MIF4GD. Interacts with rotavirus A NSP3, in this interaction, NSP3 takes the place of PABPC1 thereby inducing shutoff of host protein synthesis

De Gregorio, E. et al. (1998) RNA 4, 828-836.

Ohlmann, T. et al. (1996) EMBO J. 15, 1371-1382.

Borman, A.M. and Kean, K.M. (1997) Virology 237, 129-136.

Gradi, A. et al. (1998) Mol Cell Biol 18, 334-42.

Aliases: DKFZp686A1451 antibody, eIF 4 gamma 1 antibody, eIF 4G 1 antibody, eIF 4G1 antibody, eIF-4-gamma 1 antibody, eIF-4G 1 antibody, eIF-4G1 antibody, EIF4 gamma antibody, EIF4F antibody, EIF4G antibody, EIF4G1 antibody, EIF4G1 antibody, Eukaryotic translation initiation factor 4 gamma 1 antibody, IF4G1_HUMAN antibody, p220 antibody

UniProt:

Q04637

Application Details

Restrictions: For Research Use only


Handling

Format:	Liquid	
Buffer:	Supplied at 1.0 mg/mL in phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150 mM NaCl, 0.02 % sodium azide and 50 % glycerol.	
Preservative:	Sodium azide	
Precaution of Use:	This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which	

Handling


	should be handled by trained staff only.	
Storage:	-20 °C,-80 °C	
Storage Comment:	Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.	

Images



Immunohistochemistry

Image 1. Immunohistochemical analysis of paraffinembedded human lung carcinoma tissue using eIF4G(Phospho-Ser1232) Antibody(left) or the same antibody preincubated with blocking peptide(right).



Western Blotting

Image 2. Western blot analysis of extracts from HT29 cells untreated or treated with Anisomycin using eIF4G (phospho-Ser1231) Antibody.